Hoffmann Lab Homepage

Our goal is to develop innovative vaccine technologies against infectious diseases and gain a deeper understanding of the immunological mechanisms that shape vaccine-induced immune responses. We developed a hybrid mRNA vaccine technology that allows genetic encoding of self-assembling enveloped virus-like particles, thereby mimicking natural infection and combining attributes of mRNA- and protein nanoparticle-based vaccines. We apply this hybrid mRNA vaccine platform to design vaccines that induce potent and lasting immune responses against SARS-CoV-2, influenza, HIV-1, and cancer. We are also interested in designing vaccine strategies that focus antibody responses to conserved epitopes to enable the development of pan-coronavirus and pan-influenza vaccines.